Wells Fargo
IMRX icon

Wells Fargo’s Immuneering IMRX Stock Holding History

Wells Fargo’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$233K Buy
46,704
+29,904
+178% +$151K ﹤0.01% 5103
2026
Q1 		$88.5K Buy
16,800
+1,800
+12% +$9.23K ﹤0.01% 5170
2025
Q4 		$98.7K Hold
15,000
– – ﹤0.01% 5395
2025
Q3 		$105K Buy
15,000
+5,000
+50% +$25.9K ﹤0.01% 5288
2025
Q2 		$33.7K Buy
+10,000
New +$17.1K ﹤0.01% 5644
2024
Q2 		– Sell
-6,974
Closed -$20.2K – 7156
2024
Q1 		$20.2K Buy
6,974
+926
+15% +$5.19K ﹤0.01% 5573
2023
Q4 		$44.5K Buy
6,048
+1,328
+28% +$8.85K ﹤0.01% 5320
2023
Q3 		$36.3K Sell
4,720
-3,568
-43% -$32.8K ﹤0.01% 5347
2023
Q2 		$84K Buy
8,288
+8,162
+6,478% +$78.5K ﹤0.01% 5145
2023
Q1 		$1.22K Buy
126
+2
+2% +$11 ﹤0.01% 6322
2022
Q4 		$601 Sell
124
-997
-89% -$8.83K ﹤0.01% 6333
2022
Q3 		$16K Buy
1,121
+1,066
+1,938% +$8.46K ﹤0.01% 5504
2022
Q2 		$0 Sell
55
-9,838
-99% -$52.5K ﹤0.01% 7116
2022
Q1 		$64K Sell
9,893
-297
-3% -$2.85K ﹤0.01% 5535
2021
Q4 		$165K Buy
10,190
+10,146
+23,059% +$247K ﹤0.01% 5373
2021
Q3 		$1K Buy
+44
New +$1.18K ﹤0.01% 6719

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Wells Fargo's IMRX Position: Q2 2026 in Review

Wells Fargo increased its Immuneering (IMRX) stake by 178% in Q2 2026, buying an estimated $151K and bringing the position to 46,704 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #5103.

Wells Fargo first reported a position in IMRX in Q3 2021 and has held it in 16 quarters since. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Wells Fargo held 46,704 shares of Immuneering worth $233K as of Q2 2026.
  • Wells Fargo bought 29,904 Immuneering shares in Q2 2026, an estimated $151K.
  • Immuneering made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5103 holding.
  • Wells Fargo first reported a position in Immuneering in Q3 2021 and has held it in 16 quarters since.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.